Nuclear Imaging Systems Market: Growing Global Cancer Prevalence to Drive Market Growth to US$ 4,638.97 Million by 2031

As per the latest market research by Business Market Insights (BMI), the research report "Nuclear Imaging Systems Market Size and Forecast (2025–2031)" forecasts how the market is set to surge 26.9% by 2031. The global nuclear imaging systems market is advancing with hybrid imaging, AI integration, and new radiopharmaceuticals that improve accuracy and efficiency. PET/CT and SPECT are vital in oncology, cardiology, and neurology. Rising demand for non-invasive, early diagnosis and portable systems strengthens their role in expanding precision medicine worldwide.

The report forecasts the market to expand from US$ 3,653.86 million in 2024 to US$ 4,638.97 million by 2031, registering a robust CAGR of 3.5% over the 2025–2031 period.

The nuclear imaging systems market is growing steadily as healthcare providers focus on accurate, non-invasive tools for diagnosing complex diseases. PET/CT and SPECT systems remain the foundation of the field, playing a vital role in oncology, cardiology, and neurology. Advances such as AI-driven image analysis, improved reconstruction software, and new radiopharmaceuticals are raising both precision and efficiency. The rise of theranostics is also reshaping the market by linking imaging directly with targeted therapies, supporting the shift toward precision medicine. At the same time, portable and compact systems are making nuclear imaging more accessible in outpatient centers and smaller hospitals. With rising demand for early detection and continued investment in healthcare infrastructure worldwide, nuclear imaging is becoming an essential part of modern diagnostics.

Overview of report findings

Market Growth

The nuclear imaging systems market is projected to grow from US$ 3,653.86 million in 2024 to US$ 4,638.97 million by 2031, registering a compound annual growth rate (CAGR) of 3.5% between 2025 and 2031.

The nuclear imaging systems market is driven by rising incidence of heart and brain disorders. The market is also driven by growing global cancer prevalence, rising adoption hybrid imaging systems, and advancement such as theranostics.

Rising Cancer Incidence

The increasing prevalence of cancer worldwide is a critical driver of the Nuclear Imaging Systems market, as early and precise detection has become central to improving patient outcomes. PET/CT and SPECT systems provide functional imaging that goes beyond anatomical detail, enabling physicians to identify tumors, assess disease stage, and monitor therapy response with higher accuracy. With cancer treatment shifting toward more personalized approaches, nuclear imaging supports treatment planning by helping clinicians choose targeted therapies and evaluate effectiveness. Rising global cancer cases are inserting pressure on healthcare systems to expand oncology infrastructure, driving investment in advanced imaging technologies. As a result, hospitals, cancer centers, and private diagnostic facilities are prioritizing PET/CT and SPECT installations to meet the growing need.

Collaborations Between Academia and Industry

The nuclear imaging systems market is growing because universities, research centers, and companies are working together. These collaboration has increased the focus on creating novel radiopharmaceuticals. Then industry partners help make and sell these new products. Partnerships are providing breakthroughs in the development of radiotracers, advancing imaging for cancer and neurological evaluation, and supporting the expanding field of theranostics (diagnostics and targeting therapies sides). Collaboration is also aiding the integration of artificial intelligence into nuclear imaging to enhance workflow efficiency and diagnostic accuracy.  Alongside technology, they create training opportunities and expand access through clinical trials. By combining research expertise with commercial resources, academia–industry collaborations are strengthening the role of nuclear imaging in precision medicine worldwide.

Geographic Insights

North America is regarded as the largest nuclear imaging market, penetrated by advanced healthcare infrastructure, high acceptance rates for PET/CT and SPECT systems, and a as an advanced workforce. Strong reimbursements, focus on early disease detection, and established oncology and cardiology programs promote demand, as does an established technology drive to integrate AI-assisted image analysis, theranostics, and hybrid imaging systems. Meanwhile, compact and portable nuclear imaging units for outpatient and special needs providers continue to make nuclear imaging more accessible.

Europe is the second-largest market, marked by strong uptake of non-invasive diagnostics and a well-established network of hospitals and imaging centers. Germany, France, and the UK lead in PET/CT and SPECT adoption, supported by continuous investment in healthcare infrastructure. Growth is reinforced by advanced radiopharmaceutical production and collaborations between providers and manufacturers, which are accelerating the use of hybrid imaging systems.

Asia Pacific is the fastest-growing market, driven by rising cancer and cardiovascular disease rates, expanding healthcare infrastructure, and growing awareness of early detection. China, India, and Southeast Asia are at the forefront, supported by government initiatives, private hospital expansion, and increasing demand for compact and cost-efficient nuclear imaging systems.

Market Segmentation

• By product type, the nuclear imaging systems market is segmented into SPECT systems, PET systems and hybrid systems. The PET systems segment dominated the market in 2024.
• By application, the nuclear imaging systems market is segmented into oncology, cardiology, neurology, endocrinology and others. The oncology segment dominated the market in 2024.
• By end user, the market is segmented into hospitals, specialty clinics, diagnostics imaging centers, academic & research Institutes and others. The hospitals segment held the largest share of the market in 2024.

Competitive Strategy & Development

Key Players:

The nuclear imaging systems market is populated by several key players, each contributing to its growth and innovation. Some prominent players are:

1. GE HealthCare
2. Siemens Healthineers AG
3. Canon Inc.
4. Koninklijke Philips N.V.
5. SHIMADZU CORPORATION
6. United Imaging Healthcare Co., Ltd.
7. Neusoft Medical Systems Co., Ltd.
8. Mediso Ltd.
9. Positron Corporation
10. MiE GmbH

Trending Topics:

Hybrid X-ray Systems, Portable X-ray Imaging Devices, 3D X-ray Imaging

Global Headlines

• Canon launched Cartesion Prime SP Edition – In June 2025, Canon Medical Systems USA announced the Cartesion Prime SP Edition, a 100% air-cooled, TOF, AI-enabled Digital PET-CT, at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting. The company showcased the new system as an innovative and sustainable solution to enhance business and patient outcomes.
• GE HealthCare announced approval of Aurora nuclear medicine system – In May 2025, GE HealthCare, an American multinational medical technology company, announce that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance of its impressive Aurora nuclear medicine system and Clarify DL. This advanced dual-head SPECT/CT is designed to enhance diagnostic capabilities and streamline workflows, offering clinicians excellent image quality and operational efficiency.

Conclusion

The global market for nuclear imaging systems is expected to witness steady growth owing to the increasingly high burden of chronic diseases, such as cancer, cardiovascular diseases, and neurological diseases. PET/CT and SPECT continue to be the foundation of non-invasive diagnostics that provide functional information in addition to anatomical information. Technological advances including hybrid imaging, AI-assisted interpretation of images including new radiopharmaceuticals, theranostics, and compact systems are broadening the clinical utility of these modalities while improving efficiency, workflow and patient safety.  Challenges still exist including high costs of equipment, radiotracer supply issues, and workforce shortages of trained physicians and staff in some areas. Nevertheless, ongoing research, product development, and collaborations between academia and industry are facilitating broader acceptance. Consequently, nuclear imaging is widely accepted as a basis for early detection, personalized care, and improved health outcomes across the globe.